Enanta Pharma (ENTA) Tops Q2 EPS by 10c, Misses on Revenue

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.06), $0.10 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $15.95 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Trump: everybody is fully aware that Iran will agree to have major weapons inspections in order to ensure "nuclear honesty" long into future
• Taysha Gene Therapies (TSHA) PT Raised to $10 at BofA Securities